SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Tenax Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

88032L605

(CUSIP Number)

08/19/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP Number(s):

88032L605

Names of Reporting Persons

ING Groep N.V.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,639,666.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,639,666.00

Aggregate Amount Beneficially Owned by Each Reporting Person

2,639,666.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

7.05 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: * Based on the 37,423,917 shares of common stock of the issuer (the "Common Stock") as of July 28, 2026, as reported in the issuer's Quarterly Report on Form 10-Q for the period ended in June 30, 2026, filed with the Securities and Exchange Commission on July 31, 2026.

SCHEDULE 13G

CUSIP Number(s):

88032L605

Names of Reporting Persons

ING Capital Markets LLC

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,639,666.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,639,666.00

Aggregate Amount Beneficially Owned by Each Reporting Person

2,639,666.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

7.05 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Tenax Therapeutics, Inc.

(b)

Address of issuer's principal executive offices:

101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina 27517, USA

Item 2.

(a)

Name of person filing:

ING Groep, N.V. ING Capital Markets LLC

(b)

Address or principal business office or, if none, residence:

ING Groep N.V. PO Box 1800 Amsterdam, P7 1000 BV Amsterdam ING Capital Markets LLC 1133 Avenue of the Americas New York, NY 10036 USA

(c)

Citizenship:

ING Groep N.V. - The Netherlands ING Capital Markets LLC - Delaware

(d)

Title of class of securities:

Common Stock, $0.0001 par value per share

(e)

CUSIP Number(s):

88032L605

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

ING Groep N.V. may be deemed to be the beneficial owner of 2,639,666 Common Stock, held by ING Capital Markets LLC, a wholly owned subsidiary of ING Groep N.V. ING Capital Markets LLC may be deemed to be the beneficial owner of 2,639,666 Common Stock.

(b)

Percent of class:

Each of ING Groep N.V. and ING Capital Markets LLC may be deemed to be the beneficial owner of approximately 7.05% of Common Stock issued and outstanding as of July 28, 2026, as reported in the issuer's Quarterly Report on Form 10-Q for the period ended in June 30, 2026, filed with the Securities and Exchange Commission on July 31, 2026.

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

(ii) Shared power to vote or to direct the vote:

2639666

(iii) Sole power to dispose or to direct the disposition of:

(iv) Shared power to dispose or to direct the disposition of:

2639666

Item 5.

Ownership of 5 Percent or Less of a Class.

Not Applicable

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ING Groep N.V.

Signature:	/s/ Andreea Albu
Name/Title:	Andreea Albu, Authorized Representative
Date:	08/27/2026

Signature:	/s/ Ioana Adriana Barbu
Name/Title:	Ioana Adriana Barbu, Authorized Representative
Date:	08/27/2026

ING Capital Markets LLC

Signature:	/s/ Tyrel Tugade
Name/Title:	Tyrel Tugade, Managing Director
Date:	08/27/2026

Signature:	/s/ Anthony Masciangelo
Name/Title:	Anthony Masciangelo, Director
Date:	08/27/2026